Exelixis | EXEL - Current Liabilities

Stock Price
50.15
Daily Change
-0.95 -1.86%
Monthly
13.00%
Yearly
10.46%
Q2 Forecast
47.16

Exelixis reported $370.98M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Agios Pharmaceuticals USD 58.84M 23.36M Mar/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Bayer EUR 33.46B 875M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
Exelixis USD 370.98M 34.67M Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Incyte USD 1.49B 25.52M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.4B 408M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Takeda JPY 2.43T 180.65B Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Xencor USD 73.46M 22.45M Mar/2026